tiprankstipranks
Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
Hong Kong Market
2696
Shanghai Henlius Biotech, Inc. Class H
RESEARCH TOOLSreports

Shanghai Henlius Biotech, Inc. Class H (2696) Stock Forecast & Price Target

7 Followers
See the Price Targets and Ratings of:

2696 Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Shanghai
Henlius Biotech, Inc. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2696 Stock 12 Month Forecast

Average Price Target

HK$95.14
▲(32.69% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Shanghai Henlius Biotech, Inc. Class H in the last 3 months. The average price target is HK$95.14 with a high forecast of HK$102.91 and a low forecast of HK$89.00. The average price target represents a 32.69% change from the last price of HK$71.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"HK$21","62":"HK$62","103":"HK$103","41.5":"HK$41.5","82.5":"HK$82.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":102.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$102.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$95.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$89.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,41.5,62,82.5,103],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.55,68.42384615384616,71.2976923076923,74.17153846153846,77.04538461538462,79.91923076923077,82.79307692307692,85.66692307692307,88.54076923076923,91.41461538461539,94.28846153846153,97.16230769230769,100.03615384615384,{"y":102.91,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.55,67.82615384615384,70.10230769230769,72.37846153846154,74.65461538461538,76.93076923076923,79.20692307692308,81.48307692307692,83.75923076923077,86.03538461538461,88.31153846153846,90.58769230769231,92.86384615384615,{"y":95.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.55,67.35384615384615,69.1576923076923,70.96153846153845,72.76538461538462,74.56923076923077,76.37307692307692,78.17692307692307,79.98076923076923,81.78461538461539,83.58846153846153,85.3923076923077,87.19615384615385,{"y":89,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.5,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.5,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.5,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.5,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.05,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$102.91Average Price TargetHK$95.14Lowest Price TargetHK$89.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
SWS Res Analyst forecast on HK:2696
Unknown Analyst
SWS Res
Not Ranked
SWS Res
HK$89
Buy
24.13%
Upside
Reiterated
03/26/26
SWS Res Sticks to Their Buy Rating for Shanghai Henlius Biotech, Inc. Class H (2696)
Shenwan Hongyuan Analyst forecast on HK:2696
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$89
Buy
24.13%
Upside
Reiterated
03/26/26
Shenwan Hongyuan Sticks to Their Buy Rating for Shanghai Henlius Biotech, Inc. Class H (2696)
CMB International Securities Analyst forecast on HK:2696
Jill Wu
CMB International Securities
CMB International Securities
HK$97.75→HK$99.78
Buy
39.16%
Upside
Reiterated
03/24/26
CMB International Securities Keeps Their Buy Rating on Shanghai Henlius Biotech, Inc. Class H (2696)
CICC Analyst forecast on HK:2696
Unknown Analyst
CICC
Not Ranked
CICC
HK$102.91
Buy
43.53%
Upside
Reiterated
03/23/26
CICC Sticks to Its Buy Rating for Shanghai Henlius Biotech, Inc. Class H (2696)
Citi Analyst forecast on HK:2696
Unknown Analyst
Citi
Not Ranked
Citi
HK$95
Buy
32.50%
Upside
Reiterated
03/23/26
Shanghai Henlius Biotech, Inc. Class H (2696) Gets a Buy from Citi
Goldman Sachs Analyst forecast on HK:2696
Ziyi Chen
Goldman Sachs
Goldman Sachs
HK$100.7
Buy
40.45%
Upside
Initiated
10/30/25
Next-gen IO-ADC to lead pipeline globalization; initiate at 2025 | 9:53PM HKT | Research | Equity We initiate coverage on Buy rating and a risk-adjusted DCF-based 12-month TP of HK$100.70. Henlius Biotech is strategically evolving from an early mover in biosimilar to a global innovative biopharma. The transition is well supported by 1) an expanding pipeline led by key assets HLX43, which emerges as a potential best-in-class pan-tumor PD-L1 ADC poised for global pivotal studies; 2) a global biosimilar franchise to provide meaningful cash flow to drive R&D; and 3) early- proven global capabilities in clinical operations, regulatory affairs and biomanufacturing.
TFI Asset Management Analyst forecast on HK:2696
Unknown Analyst
TFI Asset Management
Not Ranked
TFI Asset Management
HK$120.87
Buy
68.58%
Upside
Reiterated
09/16/25
Citic Securities Analyst forecast on HK:2696
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$130
Buy
81.31%
Upside
Reiterated
08/28/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
SWS Res Analyst forecast on HK:2696
Unknown Analyst
SWS Res
Not Ranked
SWS Res
HK$89
Buy
24.13%
Upside
Reiterated
03/26/26
SWS Res Sticks to Their Buy Rating for Shanghai Henlius Biotech, Inc. Class H (2696)
Shenwan Hongyuan Analyst forecast on HK:2696
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$89
Buy
24.13%
Upside
Reiterated
03/26/26
Shenwan Hongyuan Sticks to Their Buy Rating for Shanghai Henlius Biotech, Inc. Class H (2696)
CMB International Securities Analyst forecast on HK:2696
Jill Wu
CMB International Securities
CMB International Securities
HK$97.75→HK$99.78
Buy
39.16%
Upside
Reiterated
03/24/26
CMB International Securities Keeps Their Buy Rating on Shanghai Henlius Biotech, Inc. Class H (2696)
CICC Analyst forecast on HK:2696
Unknown Analyst
CICC
Not Ranked
CICC
HK$102.91
Buy
43.53%
Upside
Reiterated
03/23/26
CICC Sticks to Its Buy Rating for Shanghai Henlius Biotech, Inc. Class H (2696)
Citi Analyst forecast on HK:2696
Unknown Analyst
Citi
Not Ranked
Citi
HK$95
Buy
32.50%
Upside
Reiterated
03/23/26
Shanghai Henlius Biotech, Inc. Class H (2696) Gets a Buy from Citi
Goldman Sachs Analyst forecast on HK:2696
Ziyi Chen
Goldman Sachs
Goldman Sachs
HK$100.7
Buy
40.45%
Upside
Initiated
10/30/25
Next-gen IO-ADC to lead pipeline globalization; initiate at 2025 | 9:53PM HKT | Research | Equity We initiate coverage on Buy rating and a risk-adjusted DCF-based 12-month TP of HK$100.70. Henlius Biotech is strategically evolving from an early mover in biosimilar to a global innovative biopharma. The transition is well supported by 1) an expanding pipeline led by key assets HLX43, which emerges as a potential best-in-class pan-tumor PD-L1 ADC poised for global pivotal studies; 2) a global biosimilar franchise to provide meaningful cash flow to drive R&D; and 3) early- proven global capabilities in clinical operations, regulatory affairs and biomanufacturing.
TFI Asset Management Analyst forecast on HK:2696
Unknown Analyst
TFI Asset Management
Not Ranked
TFI Asset Management
HK$120.87
Buy
68.58%
Upside
Reiterated
09/16/25
Citic Securities Analyst forecast on HK:2696
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$130
Buy
81.31%
Upside
Reiterated
08/28/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Shanghai Henlius Biotech, Inc. Class H

3 Months
xxx
Success Rate
5/6 ratings generated profit
83%
Average Return
+27.37%
reiterated a xxx
 rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +27.37% per trade.
1 Year
Ziyi ChenGoldman Sachs
Success Rate
1/1 ratings generated profit
100%
Average Return
+0.90%
initiated a buy rating 5 months ago
Copying Ziyi Chen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +0.90% per trade.
2 Years
xxx
Success Rate
5/6 ratings generated profit
83%
Average Return
+265.72%
reiterated a xxx
 rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +265.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2696 Analyst Recommendation Trends

Rating
Oct 25
Nov 25
Jan 26
Feb 26
Mar 26
Strong Buy
2
1
1
0
2
Buy
6
3
2
1
3
Hold
15
26
44
41
30
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
30
47
42
35
In the current month, 2696 has received 5 Buy Ratings, 30 Hold Ratings, and 0 Sell Ratings. 2696 average Analyst price target in the past 3 months is 95.14.
Each month's total comprises the sum of three months' worth of ratings.

2696 Financial Forecast

2696 Earnings Forecast

Next quarter’s earnings estimate for 2696 is HK$0.63 with a range of HK$0.63 to HK$0.63. The previous quarter’s EPS was HK$0.82. 2696 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year 2696 has its overall industry.
Next quarter’s earnings estimate for 2696 is HK$0.63 with a range of HK$0.63 to HK$0.63. The previous quarter’s EPS was HK$0.82. 2696 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year 2696 has its overall industry.

2696 Sales Forecast

Next quarter’s sales forecast for 2696 is HK$3.56B with a range of HK$3.56B to HK$3.56B. The previous quarter’s sales results were HK$3.03B. 2696 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year 2696 has its overall industry.
Next quarter’s sales forecast for 2696 is HK$3.56B with a range of HK$3.56B to HK$3.56B. The previous quarter’s sales results were HK$3.03B. 2696 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year 2696 has its overall industry.

2696 Stock Forecast FAQ

What is HK:2696’s average 12-month price target, according to analysts?
Based on analyst ratings, Shanghai Henlius Biotech, Inc. Class H’s 12-month average price target is 95.14.
    What is HK:2696’s upside potential, based on the analysts’ average price target?
    Shanghai Henlius Biotech, Inc. Class H has 32.69% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Shanghai Henlius Biotech, Inc. Class H a Buy, Sell or Hold?
          Shanghai Henlius Biotech, Inc. Class H has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Shanghai Henlius Biotech, Inc. Class H’s share price target?
            The average share price target for Shanghai Henlius Biotech, Inc. Class H is 95.14. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$102.91 ,and the lowest forecast is HK$89.00. The average share price target represents 32.69% Increase from the current price of HK$71.7.
              What do analysts say about Shanghai Henlius Biotech, Inc. Class H?
              Shanghai Henlius Biotech, Inc. Class H’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Shanghai Henlius Biotech, Inc. Class H?
                To buy shares of HK:2696, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.